Athenex announces european commission approval of klisyri® (tirbanibulin) for the topical treatment of actinic keratosis

Buffalo, n.y., july 19, 2021 (globe newswire) -- athenex, inc., (nasdaq: atnx), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced today that its partner, almirall (almirall, s.a., bme: alm), has received approval from the european commission to market klisyri® (tirbanibulin), indicated for the topical treatment of actinic keratosis (ak) of the face or scalp in adults. almirall launched klisyri in the u.s. in february 2021 and will be launching the product in europe.
ATNX Ratings Summary
ATNX Quant Ranking